Check how courts have cited this case. Use our free citator for the most current treatment.
No. 9491963
United States Court of Appeals for the Ninth Circuit
FTC v. Qyk Brands LLC
No. 9491963 · Decided April 9, 2024
No. 9491963·Ninth Circuit · 2024·
FlawFinder last updated this page Apr. 2, 2026
Case Details
Court
United States Court of Appeals for the Ninth Circuit
Decided
April 9, 2024
Citation
No. 9491963
Disposition
See opinion text.
Full Opinion
NOT FOR PUBLICATION FILED
UNITED STATES COURT OF APPEALS APR 9 2024
FOR THE NINTH CIRCUIT MOLLY C. DWYER, CLERK
U.S. COURT OF APPEALS
FEDERAL TRADE COMMISSION, No. 22-55446
Plaintiff-Appellee, D.C. No. 8:20-cv-01431-PSG-KES
v.
MEMORANDUM*
QYK BRANDS LLC, DBA Glowyy;
DRJSNATURAL LLC; RAKESH
TAMMABATTULA, individually and as an
officer of QYK Brands LLC,
DRJSNATURAL LLC, EASII, Inc., and
Theo Pharmaceuticals, Inc; JACQUELINE
THAO NGUYEN, individually and as officer
of QYK Brands LLC, DRJSNATURAL LLC
and Theo Pharmaceuticals, Inc; EASII, INC.;
THEO PHARMACEUTICALS, INC.,
Defendants-Appellants.
Appeal from the United States District Court
for the Central District of California
Philip S. Gutierrez, Chief District Judge, Presiding
Argued and Submitted September 18, 2023
San Francisco, California
Before: W. FLETCHER, RAWLINSON, and COLLINS, Circuit Judges.
Concurrence by Judge Rawlinson.
Defendants QYK Brands LLC; DRJSNATURAL LLC; EASII, Inc.; Theo
Pharmaceuticals, Inc.; Jacqueline Nguyen; and Rakesh Tammabattula appeal from
*
This disposition is not appropriate for publication and is not precedent except as
provided by Ninth Circuit Rule 36-3.
the district court’s grant of summary judgment to the Federal Trade Commission
(“FTC”) and from the district court’s ensuing final judgment awarding injunctive
and monetary relief. We have jurisdiction under 28 U.S.C. § 1291, and we affirm
in part and vacate and remand in part.
1. The FTC’s operative complaint asserted four causes of action:
(1) a claim brought under § 19(a)(1) of the FTC Act, 15 U.S.C. § 57b(a)(1),
alleging that Defendants had violated the FTC’s “Mail, Internet, or Telephone
Order Merchandise” Rule (“MITOR”), 16 C.F.R. § 435.2; see also 15 U.S.C.
§ 57a(a)(1)(B) (authorizing the FTC to issue rules specifically defining particular
acts as unfair acts within the meaning of § 5(a)); id. § 57b(a)(1) (authorizing the
FTC to bring a civil action against any person who violates such a rule);
(2) a claim brought under § 13(b) of the FTC Act, 15 U.S.C. § 53(b),
alleging that Defendants had made deceptive shipping claims in violation of § 5(a)
of the FTC Act, 15 U.S.C. § 45(a);
(3) a further § 13(b) claim alleging that Defendants had violated § 5(a), as
well as § 12 of the FTC Act, 15 U.S.C. § 52, by making deceptive claims that one
of their products (“Basic Immune IGG”) could “effectively treat, prevent
transmission of, or reduce the risk of contracting COVID-19”; and
(4) an additional § 13(b) claim alleging that Defendants had violated § 5(a)
and § 12 by making false claims that Basic Immune IGG had been “clinically
2
proven and FDA-approved to treat, prevent transmission of, or reduce the risk of
contracting COVID-19.” The district court granted summary judgment to the FTC
on each of these claims, concluding that the undisputed facts established as a
matter of law that Defendants committed the alleged violations. Reviewing de
novo, see Donell v. Kowell, 533 F.3d 762, 769 (9th Cir. 2008), we affirm that
ruling.
a. With respect to the alleged MITOR violation, Defendants contend that
the district court erroneously “applied MITOR as a strict liability rule” and thereby
failed to take account of the Covid pandemic’s disruptive effect on Defendants’
ability to fulfill their offered shipping times. We reject this contention.
Nothing in MITOR required Defendants to commit to delivery within the
short time frames that they represented, which included 3–5 days, 5–7 days, and 7–
10 days. MITOR states that it is unlawful to solicit an order “unless, at the time of
the solicitation, the seller has a reasonable basis to expect that it will be able to ship
any ordered merchandise to the buyer . . . [w]ithin that time clearly and
conspicuously stated in any such solicitation” or, “[i]f no time is clearly and
conspicuously stated, within thirty (30) days after receipt of a properly completed
order from the buyer.” See 16 C.F.R. § 435.2(a)(1) (emphasis added). Undisputed
evidence shows that Defendants lacked a reasonable basis to expect that they
would be able to satisfy their advertised shipping-time claims. At the time that
3
they were continuing to post hand-sanitizer advertisements that said, “In Stock &
Ships Today,” Defendants had limited inventory and were aware of shipping
issues, and yet they processed orders for nearly 150,000 bottles in two weeks.
Defendants admit that Tammabattula “became aware of the ‘full gravity of the
situation’” regarding shipping delays by March 12 or 13, 2020, and that
Tammabattula thereafter knew that they “could not keep up with demand.”
Defendants plainly had no reasonable basis to expect that they could meet the
shipping times they continued to advertise, and they thereby violated MITOR.
And, for the same reason, they also made deceptive shipping claims in violation of
§ 5 of the FTC Act.
Moreover, if (as Defendants contend) post-order events make it impossible
to fulfill an order within the time stated, MITOR provides that the seller must
“offer to the buyer, clearly and conspicuously and without prior demand, an option
either to consent to a delay in shipping or to cancel the buyer’s order and receive a
prompt refund.” 16 C.F.R. § 435.2(b)(1); see also id. (stating that any such “offer
shall be made within a reasonable time after the seller first becomes aware of its
inability to ship within the applicable time set forth in paragraph (a)(1) of this
section”). MITOR thus has built into its structure an accommodation for
unforeseen disruptions. What MITOR does not allow is for sellers to do what
Defendants did here, which is to provide shipping estimates that, at the time those
4
estimates were made, Defendants had no reasonable basis to believe would be met.
Id. § 435.2(a)(1). In addition, Defendants undisputedly failed, in many cases, to
offer customers an actual opportunity to cancel the order and receive a refund. Id.
§ 435.2(b)(1). For example, Defendants informed some customers that orders
could not be canceled after the creation of a shipping label and that, if they desired
a refund, they would have to await their late shipment and then send it back to
Defendants.
b. With respect to the alleged false representations concerning Basic
Immune IGG, Defendants contend that there was a disputed issue of fact as to what
representations Nguyen made in an interview on a Vietnamese-language television
channel. Specifically, Defendants point to Nguyen’s declaration providing her
own English-language translation of the key statements she made in Vietnamese
during that interview, and Defendants argue that the district court improperly
resolved a resulting factual dispute as to the actual meaning of what she had said.
This contention fails. A declaration proffered in response to a summary judgment
motion “must . . . set out facts that would be admissible in evidence[] and show
that the . . . declarant is competent to testify on the matters stated.” FED. R. CIV. P.
56(c)(4). But as the district court noted, Nguyen’s declaration failed to provide
any foundation for concluding that she is “competen[t] to testify as a Vietnamese
to English translator.” This evidentiary ruling was not an abuse of discretion. See
5
Sandoval v. County of San Diego, 985 F.3d 657, 665 (9th Cir. 2021) (“Evidentiary
rulings made in the context of summary judgment motions are reviewed for abuse
of discretion.” (citation omitted)). With that contrary evidence properly excluded,
there was no genuine issue of material fact as to the English translation of the
statements made.
2. The district court ordered monetary relief in the form of consumer
refunds, invoking the authority conferred under § 19(b) of the FTC Act.
Specifically, the court ordered Defendants to pay over to the FTC $3,086,239.99,
which represented Defendants’ net revenue from hand sanitizer sales from March
to August 2020. Those funds were then to be used to provide full-price refunds to
consumers, but only if the consumer affirmatively submitted a “request for a
refund” within a 120-day period following notification of the refund program. At
the conclusion of the 120-day period, the FTC would then be required to
“determine the amount of unclaimed funds” left and then to “return to Defendants”
that amount, “less costs of administering the Redress Fund.” Defendants challenge
the scope of the monetary relief order, but we discern no abuse of discretion. See
FTC v. Figgie Int’l, Inc., 994 F.2d 595, 607 (9th Cir. 1993).
a. The undisputed facts concerning the unrealistic shipping representations
made by Defendants in their internet advertising over an extended period of time
are unquestionably sufficient to give rise to a presumption that consumer orders
6
placed during that time period were made in reliance on such material
representations and that consumers were injured by the shipping delays. Figgie,
994 F.2d at 605–06 (holding that, once the FTC “has proved that the defendant
made material misrepresentations, that they were widely disseminated, and that
consumers purchased the defendant’s product,” a “presumption of actual reliance
arises” and, if unrebutted, “injury to consumers has been established”).
Defendants have failed to put forward sufficient evidence to rebut this
presumption. Defendants posit that only 11% of their sales were attributable to the
“In Stock & Ships Today” Google advertising campaign, and they therefore
contend that the district court erred in applying the Figgie presumption to all
purchasers. But this argument overlooks the fact that this Google advertising
campaign was not the only time that Defendants made unrealistic claims about
delivery timeframes: although the precise time estimates varied, such claims were
also made on Defendants’ websites and a variety of other social media platforms.
Moreover, Defendants’ 11% figure is based on an unexplained estimate in a
declaration from Tammabattula that lacks adequate foundation. The FTC suggests
that the 11% figure “includes only those consumers who clicked on the [Google]
ad’s link to make their purchase,” but there is no basis in the record to conclude
that such click-throughs are the only purchases that were made in reliance on such
advertising.
7
Defendants also contend that some customers were satisfied with their hand
sanitizer, because “there were hundreds of repeat customers,” some percentage of
customers did receive products within the requisite timeframes, and some
customers even sent compliments. We conclude that any such issues were
adequately addressed by the district court’s requirement that monetary refunds
could only be provided under the court’s remedial order to those consumers who
affirmatively asked for one.
b. Defendants also argue that, even if the district court’s remedial order
could be said to adequately target its monetary relief to injured consumers, the
court should not have afforded a full-price refund to all such consumers, especially
without any requirement to return the product. On the specific facts of this case,
we find no abuse of discretion.
The listed expiration period for the hand sanitizer products was two years,
and at the time of the district court’s remedial ruling on April 22, 2022, much of
the product at issue would already have expired. Moreover, by the time that the
FTC would be able to set up the contemplated refund program and provide
notification to consumers, the relevant product would have expired by the end of
the 120-day period for requesting refunds. Under these unique circumstances,
imposing a requirement to return expired or about-to-expire products could
reasonably be viewed as pointless and of no value. On that basis, we conclude that
8
the district court did not abuse its discretion in failing to require return of the
products as a condition for receiving a full refund.
Defendants also assert that providing full refunds to consumers whose
product was only one or two days late overcompensates them for any asserted
injury from the delay. We conclude that, in light of the requirement that no
refunds would be given unless a particular consumer affirmatively made such a
request, the district court did not abuse its discretion. That limitation could
reasonably be deemed sufficient to screen out any consumers who experienced
only a de minimis delay. And for those who experienced a material delay, a
uniform monetary award is a reasonable approximation of individual consumer
injury, particularly given the relatively modest price of the sanitizer and the
urgency with which consumers sought such products at the beginning of the
pandemic.
3. Defendants also raise a number of challenges to the district court’s award
of injunctive relief. We conclude that, with one exception, the district court did not
abuse its discretion.
a. The district court did not abuse its discretion in concluding that there was
a sufficient likelihood of future violations to warrant the imposition of an
injunction. See FTC v. Evans Prods. Co., 775 F.2d 1084, 1087 (9th Cir. 1985)
(holding that, as a general rule, injunctive relief under § 13(b) is available “only if
9
the wrongs are ongoing or likely to recur”); see also CFPB v. Gordon, 819 F.3d
1179, 1197 (9th Cir. 2016) (stating that a grant of permanent injunctive relief is
reviewed for abuse of discretion).
Defendants argue that, in finding that they acted with a “high degree of
scienter” in connection with the hand sanitizer sales, the district court
misconstrued, as attributable to QYK, general comments that Tammabattula made
in a podcast about the difficulties of obtaining sufficient supplies to keep up with
demand. This contention is refuted by the podcast itself. In it, Tammabattula
prefaces his remarks as reflecting his company’s “firsthand” experience in being
“one of the few companies here in the U.S. that’s trying to produce [personal
protective equipment (‘PPE’)] domestically,” an experience that allowed them to
“see all the challenges here.” Moreover, the district court also relied on ample
additional undisputed facts concerning Defendants’ awareness of the scope of the
problems concerning supply chains and shipping delays.
Defendants also emphasize that the violations occurred only over a period of
several months rather than several years and that they recently changed their
business model to avoid the sort of direct retail sales that were involved in the
violations at issue here. While these are factors that arguably weigh in favor of
declining to impose an injunction, the district court reached a contrary conclusion
after considering these factors in light of other considerations that, in its view,
10
reflected a potential willingness and continued opportunity to engage in violations
of the FTC Act. On the undisputed underlying facts in this record, we cannot say
that the decision to impose an injunction was an abuse of discretion.
b. Finally, Defendants challenge the scope of the injunction. Specifically,
Defendants argue that the injunction is overbroad to the extent that it permanently
bars all Defendants from “advertising, marketing, promoting, or offering for sale,
. . . any Protective Goods and Services,” which the injunction defines as “any good
or service designed, intended, or represented to detect, treat, prevent, mitigate, or
cure COVID-19 or any other infection or disease.”
“To determine if an injunction is overbroad, we consider ‘(1) the seriousness
and deliberateness of the violation; (2) [the] ease with which the violative claim
may be transferred to other products; and (3) whether the [defendant] has a history
of prior violations.’” FTC v. Grant Connect, LLC, 763 F.3d 1094, 1105 (9th Cir.
2014) (citation omitted). Our review is for abuse of discretion, id. at 1101, and we
will uphold the injunction “so long as it bears a ‘reasonable relation to the unlawful
practices found to exist,’” id. at 1105 (quoting FTC v. Colgate-Palmolive Co., 380
U.S. 374, 394–95 (1965)). Under these standards, we conclude that the injunction
is overbroad only with respect to Defendant Tammabattula.
The district court’s decision to permanently bar Nguyen and the corporate
11
Defendants1 from the “Protective Goods and Services” industry was not an abuse
of discretion. As the district court correctly noted, Nguyen was “a licensed
pharmacist who had her pharmacy license suspended” for serious misconduct,
including acts of dishonesty, all of which was documented in the record. Given
her willingness to then make false health claims to sell products during the
pandemic (i.e., Basic Immune IGG), the district court acted well within its
discretion in concluding that she and the Defendant corporations should be
enjoined from further participation in the selling of goods or services for the
detection, treatment, prevention, mitigation, or cure of illness. FTC v. Gill, 265
F.3d 944, 957 (9th Cir. 2001).
We reach a different conclusion as to Defendant Tammabattula.2
Tammabattula’s wrongful conduct in this case was limited to the false shipping
claims respecting the hand sanitizer. The record does not reflect that he had any
1
In the district court, the parties agreed that the various corporate Defendants all
“operated as a common enterprise” and that each corporate Defendant “is liable for
the acts and practices alleged” in the operative complaint. Because Nguyen acted
through one or more of these corporate Defendants, who are in turn each
concededly fully responsible for each other, any injunctive relief that is appropriate
as to Nguyen would properly also extend to all of the corporate Defendants.
2
The FTC contends that Defendants failed to object to the district court’s inclusion
of Tammabattula in the injunction below. But even assuming arguendo that our
review is only for plain error, Draper v. Rosario, 836 F.3d 1072, 1084–85 (9th Cir.
2016), we conclude that the plain-error standard is met here. For the reasons we
explain, the district court’s decision to subject Tammabattula to the same
injunction as Nguyen and the corporate Defendants was an obvious error that
should be corrected in order to prevent a miscarriage of justice. Id.
12
personal involvement in Nguyen’s prior misconduct as a pharmacist or in her
misrepresentations regarding Basic Immune IGG. Moreover, in contrast to the
corporate Defendants, there was no agreement below that Nguyen and
Tammabattula were fully liable for each other’s conduct, such that any injunction
against Nguyen could automatically be extended, in every respect, to
Tammabattula. Tammabattula’s first-time violation did not reasonably support
including him, personally, in the sweeping permanent industry ban imposed by the
district court.3 Cf. Grant Connect, 763 F.3d at 1097–98, 1105 (upholding
permanent injunction entered against defendant whose “business practices ha[d]
drawn FTC scrutiny for over a decade[] and ha[d] resulted in three distinct
enforcement actions against him”). We leave it to the district court, on remand, to
exercise its discretion in determining whether, and to what extent, a more suitably
tailored injunction should be imposed with respect to Tammabattula.
For the foregoing reasons, we vacate the injunction as to Tammabattula
personally and remand for further proceedings consistent with this decision. The
judgment of the district court is otherwise affirmed in all respects.
AFFIRMED IN PART, VACATED IN PART, AND REMANDED.
3
We do not disturb the injunction to the extent that it prohibits any person
(including Tammabattula) from acting “in active concert or participation” with
Nguyen or the corporate Defendants in violation of the injunction as to them. We
vacate the injunction only insofar as it applies fully to Tammabattula with respect
to his future conduct independent of Nguyen or the corporate Defendants.
13
FILED
FTC v. QYK Brands, LLC, Case No. 22-55446
APR 9 2024
Rawlinson, Circuit Judge, concurring in the result:
MOLLY C. DWYER, CLERK
U.S. COURT OF APPEALS
I concur in the result.
1
Plain English Summary
NOT FOR PUBLICATION FILED UNITED STATES COURT OF APPEALS APR 9 2024 FOR THE NINTH CIRCUIT MOLLY C.
Key Points
01NOT FOR PUBLICATION FILED UNITED STATES COURT OF APPEALS APR 9 2024 FOR THE NINTH CIRCUIT MOLLY C.
02MEMORANDUM* QYK BRANDS LLC, DBA Glowyy; DRJSNATURAL LLC; RAKESH TAMMABATTULA, individually and as an officer of QYK Brands LLC, DRJSNATURAL LLC, EASII, Inc., and Theo Pharmaceuticals, Inc; JACQUELINE THAO NGUYEN, individually and as officer
03Gutierrez, Chief District Judge, Presiding Argued and Submitted September 18, 2023 San Francisco, California Before: W.
04Defendants QYK Brands LLC; DRJSNATURAL LLC; EASII, Inc.; Theo Pharmaceuticals, Inc.; Jacqueline Nguyen; and Rakesh Tammabattula appeal from * This disposition is not appropriate for publication and is not precedent except as provided by Nin
Frequently Asked Questions
NOT FOR PUBLICATION FILED UNITED STATES COURT OF APPEALS APR 9 2024 FOR THE NINTH CIRCUIT MOLLY C.
FlawCheck shows no negative treatment for FTC v. Qyk Brands LLC in the current circuit citation data.
This case was decided on April 9, 2024.
Use the citation No. 9491963 and verify it against the official reporter before filing.